|
|
Title:
Hyaluronic
acid gel, process for producing the same, and medical material containing
the same
United States Patent: 7,014,860
Issued: March 21, 2006
Inventors: Kawata; Masatoshi (Tokyo, JP);
Okamoto; Akio (Tokyo, JP); Miyata; Yoshiaki (Tokyo, JP); Ohshima; Kazuhiro
(Tokyo, JP); Yamamoto; Osamu (Tokyo, JP); Miyoshi; Teruzou (Tokyo, JP);
Arai; Kazuhiko (Niigata, JP); Kitagawa; Hironoshin (Tokyo, JP); Umeda;
Toshihiko (Tokyo, JP); Kaneko; Hiroshi (Tokyo, JP)
Assignee: Denki Kagaku Kogyo Kabushiki
Kaisha (Tokyo, JP)
Appl. No.: 182467
Filed: February 3, 2000
PCT Filed: February 3, 2000
PCT NO: PCT/JP00/00582
371 Date: July 29, 2002
102(e) Date: July 29, 2002
PCT PUB.NO.: WO01/57093
PCT PUB. Date: August 9, 2001
|
|
|
Executive MBA in Pharmaceutical Management, U. Colorado
|
Abstract
Production of a hyaluronic acid gel,
which comprises keeping hyaluronic acid in water at a hyaluronic acid
concentration of at least 5 wt % in the presence of an acid component in
an amount at least equimolar with the carboxyl groups in the hyaluronic
acid.
DISCLOSURE OF THE
INVENTION
Namely, the present invention provides
(1) a method of producing a hyaluronic acid gel, which comprises keeping
hyaluronic acid in water at a hyaluronic acid concentration of at least 5
wt % in the presence of an acid component in an amount at least equimolar
with the carboxylic groups in the hyaluronic acid, (2) the method of
producing a hyaluronic acid gel according to (1), which comprises keeping
hyaluronic acid in water at a hyaluronic acid concentration of at least 5
wt % in the presence of an acid component in an amount at least equimolar
with the carboxyl groups in the hyaluronic acid at from -10° C. to 30° C.,
(3) a method of producing a hyaluronic acid gel, which comprises keeping
hyaluronic acid in water at a hyaluronic acid concentration of at least 5
wt % in the presence of an acid component in an amount at least equimolar
with the carboxyl groups in the hyaluronic acid at from -10° C. to 30° C.
to form a hyaluronic acid gel and treating the gel with a neutralizing
liquid, (4) a method of producing a hyaluronic acid gel, which comprises
keeping an acidic hyaluronic acid aqueous solution containing hyaluronic
acid at a concentration of at least 5 wt % and an acid component in an
amount at least equimolar with the carboxyl groups in the hyaluronic acid
at from -10° C. to 30° C. to form a hyaluronic acid gel and treating the
gel with a neutralizing liquid, (5) a method of producing a hyaluronic
acid gel, which comprises keeping an acidic hyaluronic acid mixture
obtained by mixing hyaluronic acid and an acidic aqueous solution
containing an acid component in an amount at least equimolar with the
carboxyl groups in the hyaluronic acid to a hyaluronic acid concentration
of at least 5 wt % based on the acidic aqueous solution at from -10° C. to
30° C. to form a hyaluronic acid gel and treating the gel with a
neutralizing liquid, (6) a method of producing a hyaluronic acid gel,
which comprises keeping hyaluronic acid impregnated with an acidic aqueous
solution containing an acid component in an amount at least equimolar with
the carboxyl groups in the hyaluronic acid to a hyaluronic acid
concentration of at least 5 wt % based on the acidic aqueous solution at
from -10° C. to 30° C. to form a hyaluronic acid gel and treating the gel
with a neutralizing liquid, (7) a gel made of hyaluronic acid alone which
is hardly soluble in a neutral aqueous solution and has transparency, (8)
the hyaluronic acid gel according to (7), which dissolves in a neutral
aqueous solution at 25° C. in one day to a degree of dissolution of at
most 50%, (9) the hyaluronic acid gel according to (7), which dissolves to
yield solubilized hyaluronic acid having a branched structure and partly
containing a molecular weight fraction with a branching degree of at least
0.5, when treated under accelerating conditions for acid hydrolysis of
hyaluronic acid, (10) a biomedical material containing a gel made of
hyaluronic acid alone which has transparency and dissolves in a neutral
aqueous solution at 25° C. in one day to a degree of dissolution of at
most 50%, (11) a biomedical material containing a gel made of hyaluronic
acid alone which satisfies the following requirement and has transparency:
the hyaluronic acid gel dissolves to yield solubilized hyaluronic acid
having a branched structure and partly containing a molecular weight
fraction with a branching degree of at least 0.5, when treated under
accelerating conditions for acid hydrolysis of hyaluronic acid, (12) a
biomedical material containing a hyaluronic acid gel having transparency
and un-gelled hyaluronic acid, wherein the hyaluronic acid gel dissolves
in a neutral aqueous solution at 25° C. in one day to a degree of
dissolution of at most 50%, and dissolves to yield solubilized hyaluronic
acid having a branched structure and partly containing a molecular weight
fraction with a branching degree of at least 0.5, when treated under
accelerating conditions for acid hydrolysis of hyaluronic acid, (13) the
biomedical material according to any one of (10) to (12), wherein the
hyaluronic acid gel having transparency is flaky, (14) the biomedical
material according to any one of (10) to (13), which is an injection for
treatment of arthrosis, (15) the biomedical material according to any one
of (10) to (13), which is an embolizing material, (16) the biomedical
material according to any one of (10) to (13), which is an injection for a
soft tissue, and (17) the biomedical material according to any one of (10)
to (13), which is an artificial vitreous body.
The present invention provides a hardly water soluble hyaluronic acid gel
made of hyaluronic acid alone with transparency. The hyaluronic acid gel
according to the present invention retains the structure of the
biologically inherent hyaluronic acid by virtue of obviation of use of
crosslinkers, and is excellently safe and biocompatible. Therefore, it is
useful as a biomedical material such as an injection for treatment of
arthrosis, an embolizing material, an injection for a soft tissue and an
artificial vitreous body.
BEST MODE FOR
CARRYING OUT THE INVENTION
Now, the present invention will be
described below in detail.
In the present invention, hyaluronic acid obtained by extraction from
animal tissues or by fermentation may be used without any restriction on
its source.
The strain used in fermentation is preferably a hyaluronic acid-producing
microorganism isolated from nature such as the genus Streptococcus
or a mutant which steadily produces hyaluronic acid in high yield such as
Streptococcus equi FM-100 (accession number 9027 given by National
Institute of Bioscience and Human-Technology) disclosed in JP-A-63-123392
or Streptococcus equi FM-300 (accession number 2319 given by
National Institute of Bioscience and Human-Technology) disclosed in
JP-A-2-234689. Pure hyaluronic acid obtained from cultures of the
above-mentioned mutants may be used.
The molecular weight of the hyaluronic acid to be used in the present
invention is preferably within the range of from about 1×105 to
about 1×107 Da. Hyaluronic acid having a higher molecular
weight may also be used after the molecular weight is lowered into this
range by treatment such as hydrolysis.
In the present invention, the concept of hyaluronic acid is used so as to
include its alkali metal salts such as sodium, potassium and lithium
salts, too.
In the present invention, by hyaluronic acid alone, it is meant that no
chemical crosslinker or chemical modifier is used other than hyaluronic
acid, that hyaluronic acid is not in the form of a complex with a cationic
polymer, and that the gel is an auto-crosslinked gel.
On the other hand, substances which do not directly induce introduction of
a crosslinked structure into hyaluronic acid or make hyaluronic acid
insoluble or hardly soluble may be added when the hyaluronic acid gel
according to the present invention is prepared.
Further, in preparation of a hyaluronic acid gel, pharmacologically or
physiologically active substances may be added to give a hyaluronic acid
gel containing such substances without any restriction.
The hyaluronic acid gel according to the present invention is
characterized in that it is hardly soluble in a neutral aqueous solution.
In the present invention, the difficulty in dissolution is defined by the
solubility in a neutral aqueous solution at 25° C. and means that the gel
dissolves in a neutral aqueous solution at 25° C. in 12 hours to a degree
of dissolution of at most 50%, preferably at most 30%, particularly
preferably at most 10%.
The hyaluronic acid gel according to the present invention is a polymer
having a three dimensional network structure or its swollen product. The
three dimensional network structure is made of crosslinked hyaluronic
acid.
The hyaluronic acid gel according to the present invention can be
solubilized through degradation by treatment under accelerating conditions
for acid hydrolysis of hyaluronic acid. When the solubilized hyaluronic
acid retains the crosslinked structure, it is distinguished as branched
hyaluronic acid from linear hyaluronic acid according to the theory of
polymer solution.
The accelerating conditions for acid hydrolysis of hyaluronic acid
according to the present invention are preferably such that the pH of the
aqueous solution is 1.5 and the temperature is 60° C. It is well known
that cleavage of the main chain of hyaluronic acid through hydrolysis of
glycosidic bonds is remarkably accelerated in an acidic or alkaline
aqueous solution as compared with that in a neutral aqueous solution. In
addition, acid hydrolysis is accelerated at a higher temperature.
In the present invention, the molecular weights and branching degrees of
the fractions separated by GPC according to molecular weight are measured
on-line continuously by the GPC-MALLS method. In the present invention,
the branching degree was measured by the elution volume method which
compares the molecular weight of each fraction of the solubilized
hyaluronic acid with the molecular weight of a fraction at the same
elution volume of linear hyaluronic acid as a control. The branching
degree is the number of branch points in one polymer chain of the
solubilized hyaluronic acid and plotted against the molecular weight of
the solubilized hyaluronic acid. Measurement of the branching degree by
the GPC-MALLS method by the elution volume method is described in
PCT/JP98/03536.
Solubilized hyaluronic acid was diluted with the GPC eluent for
concentration adjustment and filtered through a membrane filter of 0.2 μm
before measurement.
If the hyaluronic acid gel according to the present invention has a
crosslinked structure which is stable under accelerating conditions for
acid hydrolysis of hyaluronic acid, a branched structure is recognized in
the solubilized hyaluronic acid according to the theory of polymer
solution. The hyaluronic acid gel according to the present invention has a
branching degree of at least 0.5.
In the present invention, transparency means that the visible light
transmittance of the hyaluronic acid gel of the present invention in a
spectrometric cuvette of 10 mm thick measured at 340 nm to 800 nm is at
least 50%, preferably 70%, particularly preferably 90%, based on the
transmittance of water.
The transparent hyaluronic acid gel of the present invention is obtained
by keeping hyaluronic acid in water at a hyaluronic acid concentration of
at least 5 wt % in the presence of an acid component in an amount at least
equimolar with the carboxyl groups in the hyaluronic acid, without
freezing.
The amount of the acid component to be used for acidification in the
present invention is usually preferred to be at least equimolar with the
carboxyl groups in hyaluronic acid, although it is set depending on
various factors such as the type of the counterion in the hyaluronic acid
salt, the molecular weight of hyaluronic acid, the concentration of
hyaluronic acid and the properties of the resulting gel such as strength.
As the acid component, any acid that is stronger than hyaluronic acid in
acidity may be used. Preferably, a strong acid such as hydrochloric acid,
nitric acid and sulfuric acid is used to decrease the amount of an acid.
When the hyaluronic acid concentration is below 5 wt %, a hyaluronic acid
gel is not obtained, whether or not a sufficient proportion of the
carboxyl groups in the hyaluronic acid undergo protonation.
In the present invention, it is necessary to put hyaluronic acid, water
and an acid component in an amount at least equimolar with the carboxyl
groups in the hyaluronic acid together so that the hyaluronic acid
concentration is 5 wt %, and then keep their coexistence so that gellation
proceeds, for example, by letting them stand until a certain period of
time passes.
Further, though the keeping temperature and time are set depending on
various factors such as the type of the counterion in the hyaluronic acid
salt, the molecular weight of hyaluronic acid, the concentration of
hyaluronic acid and the properties of the resulting gel such as strength,
the temperature is preferably from -10° C. to 30° C. to prevent water from
freezing and prevent acid decomposition of hyaluronic acid.
If the acidic hyaluronic acid aqueous solution freezes, an opaque
hyaluronic acid gel is obtained.
The acidic hyaluronic acid aqueous solution with a hyaluronic acid
concentration of at least 5 wt % to be used in the present invention may
be prepared by any methods, for example, by mixing hyaluronic acid with an
acidic aqueous solution, by impregnating hyaluronic acid with an acidic
aqueous solution, by concentrating a low concentration acidic hyaluronic
acid aqueous solution to a predetermined concentration or by adding an
acid component to a dense hyaluronic acid aqueous solution.
In the present invention, hyaluronic acid may be used in any form, for
example, in powdery form, in the form of a molded block obtained from
hyaluronic acid powder by compacting or in the form of a cast film or a
sponge obtained from an aqueous solution of hyaluronic acid in distilled
water by air-drying or freeze-drying. The mixing of hyaluronic acid with
an acidic aqueous solution may be accomplished by addition of the acidic
aqueous solution to hyaluronic acid and subsequent kneading.
The impregnation of hyaluronic acid with an acidic aqueous solution may be
conducted so as to attain a predetermined hyaluronic acid concentration.
In the case where a dilute acidic hyaluronic acid aqueous solution is
concentrated to a predetermined concentration, the low concentration
acidic hyaluronic acid aqueous solution is prepared firstly by adding an
acid component to hyaluronic acid dissolved in distilled water or
dissolving hyaluronic acid directly in an acidic aqueous solution and may
be prepared from any form of hyaluronic acid. The low concentration is
intended to be lower than the hyaluronic acid concentration of the
intended hyaluronic acid gel and is preferably lower than 5 wt % for easy
handling. The concentration may be accomplished by ultracentrifugation,
air-drying, vacuum drying or freeze-drying.
In the case where an acid component is added to a dense hyaluronic acid
aqueous solution, the dense hyaluronic acid aqueous solution is prepared
firstly by mixing hyaluronic acid with distilled water or by concentrating
a dilute hyaluronic acid aqueous solution and may be prepared from any
form of hyaluronic acid. The addition of an acid component to the dense
hyaluronic acid aqueous solution may be accomplished by exposure to an
atmosphere of a gaseous acid such as hydrogen chloride or by immersion in
a solution of an acid in a solvent with little solvency for hyaluronic
acid such as an ethanol-hydrochloric acid solution.
The hyaluronic acid gel obtained in accordance with the present invention
has to be subjected to neutralization of hyaluronic acid in the acid form
in which the carboxyl groups have protonated and the acid component used
for acidification in order to avoid acid hydrolysis of hyaluronic acid.
For neutralization, an aqueous solvent such as phosphate buffer or aqueous
sodium hydroxide is usually used, though there is no restriction on the
aqueous solvent so long as it does not functionally impair the hyaluronic
acid gel.
Herein, such a solvent is generically referred to as a neutralizing
liquid.
Although there is no particular restriction on the treatment with a
neutralizing liquid (the neutralization method), a batch method, a
filtration method or a method in which a solvent is passed through a
loaded column is usually used. The neutralization conditions, inclusive of
the volume of the neutralization liquid and the number of times of
neutralization, may be selected appropriately considering the shape and
the use of the hyaluronic acid gel so that hyaluronic acid in the acid
form and the acid component used for acidification are neutralized.
The hyaluronic acid gel treated with a neutralizing liquid is used in an
immersed state with a solvent, in a wet state with a solvent or in a dry
state after air-drying, vacuum drying or freeze drying depending on the
use.
With a view to shaping the hyaluronic acid gel, by selecting hyaluronic
acid, the vessel for the acidic hyaluronic acid aqueous solution and the
procedure, a hyaluronic acid gel of desired shape such as a sheet-like,
filmy, flaky, spongy, massive or tubular shape can be obtained. For
example, from compacted hyaluronic acid power, a gel in the form of a
block or a sheet is obtained. Preparation of a hyaluronic acid gel may be
followed by post-treatment such as mechanical fragmentation,
freezing-thawing, rolling or spinning to make the gel into fine flakes, a
sponge, a film or the like.
The hyaluronic acid gel of the present invention is obtainable endotoxin-free
and aseptically if care is taken over the reagents, water and the vessels.
The hyaluronic acid gel thus prepared is transparent in itself and retains
transparency even after crushed and suspended. It may be filled into a
syringe or a bag before use. If pharmaceutically or physiologically active
substances are added at the time of gelation, the resulting hyaluronic
acid gel contains these substances in it.
For example, addition of thrombin which coagulates blood by catalyzing
conversion of fibrinogen into fibrin in the blood coagulation cascade with
a view to accelerating embolization and addition of various antitumor
agents with a view to obstructing tumor arteries may be mentioned without
any restriction.
The hyaluronic acid gel of the present invention shows great improvement
in in vivo residency and persistency over hyaluronic acid solution and
excellently safe and biocompatible by virtue of the absence of
crosslinkers. Therefore, it can be used as a biomedical material such as
an injection for treatment of arthrosis, an embolizing material, an
injection for a soft tissue and an artificial vitreous body.
Claim 1 of 21 Claims
1. A biomedical
material which contains a transparent gel consisting of hyaluronic acid or a
salt thereof; a second acid or a salt thereof; and water;
wherein the transparent gel does not contain any cross-linkers, and
wherein at least one of the following requirements (a), (b) and (c) is
satisfied:
(a) the hyaluronic acid gel dissolves in a neutral aqueous solution at 25°
C. in one day to a degree of dissolution of at most 50%,
(b) the hyaluronic acid gel dissolves to yield a solubilized hyaluronic acid
having a branched structure and partly containing a molecular weight
fraction with a branching degree of at least 0.5, when treated under
accelerating conditions for acid hydrolysis of hyaluronic acid, or
(c) the hyaluronic acid gel satisfies the above requirements (a) and (b),
and the biomedical material also contains an un-gelled hyaluronic acid.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|